Copyright Reports & Markets. All rights reserved.

Asia-Pacific Antidiabetic SGLT-2 Inhibitor Market Report 2018

Request for Sample of this report
Buy now

Table of Contents

    1 Report Overview

    • 1.1 Definition and Specification
    • 1.2 Report Overview
      • 1.2.1 Manufacturers Overview
      • 1.2.2 Regions Overview
      • 1.2.3 Type Overview
      • 1.2.4 Application Overview
    • 1.3 Industrial Chain
      • 1.3.1 Antidiabetic SGLT-2 Inhibitor Overall Industrial Chain
      • 1.3.2 Upstream
      • 1.3.3 Downstream
    • 1.4 Industry Situation
      • 1.4.1 Industrial Policy
      • 1.4.2 Product Preference
      • 1.4.3 Economic/Political Environment
    • 1.5 SWOT Analysis

    2 Market Analysis by Types

    • 2.1 Overall Market Performance(Volume)
      • 2.1.1 Canagliflozin Market Performance (Volume)
      • 2.1.2 Empagliflozin Market Performance (Volume)
      • 2.1.3 Dapagliflozin Market Performance (Volume)
      • 2.1.4 Other Market Performance (Volume)
    • 2.2 Overall Market Performance(Value)
      • 2.1.1 Canagliflozin Market Performance (Value)
      • 2.1.2 Empagliflozin Market Performance (Value)
      • 2.1.3 Dapagliflozin Market Performance (Value)
      • 2.1.4 Other Market Performance (Value)

    3 Product Application Market

    • 3.1 Overall Market Performance (Volume)
      • 3.1.1 Hospitals Market Performance (Volume)
      • 3.1.2 Clinics Market Performance (Volume)
      • 3.1.3 Other Market Performance (Volume)

    4 Manufacturers Profiles/Analysis

    • 4.1 Pfizer
      • 4.1.1 Pfizer Profiles
      • 4.1.2 Pfizer Product Information
      • 4.1.3 Pfizer Antidiabetic SGLT-2 Inhibitor Business Performance
      • 4.1.4 Pfizer Antidiabetic SGLT-2 Inhibitor Business Development and Market Status
    • 4.2 AstraZeneca
      • 4.2.1 AstraZeneca Profiles
      • 4.2.2 AstraZeneca Product Information
      • 4.2.3 AstraZeneca Antidiabetic SGLT-2 Inhibitor Business Performance
      • 4.2.4 AstraZeneca Antidiabetic SGLT-2 Inhibitor Business Development and Market Status
    • 4.3 Johnson & Johnson
      • 4.3.1 Johnson & Johnson Profiles
      • 4.3.2 Johnson & Johnson Product Information
      • 4.3.3 Johnson & Johnson Antidiabetic SGLT-2 Inhibitor Business Performance
      • 4.3.4 Johnson & Johnson Antidiabetic SGLT-2 Inhibitor Business Development and Market Status
    • 4.4 GlaxoSmithKline
      • 4.4.1 GlaxoSmithKline Profiles
      • 4.4.2 GlaxoSmithKline Product Information
      • 4.4.3 GlaxoSmithKline Antidiabetic SGLT-2 Inhibitor Business Performance
      • 4.4.4 GlaxoSmithKline Antidiabetic SGLT-2 Inhibitor Business Development and Market Status
    • 4.5 Merck & Co
      • 4.5.1 Merck & Co Profiles
      • 4.5.2 Merck & Co Product Information
      • 4.5.3 Merck & Co Antidiabetic SGLT-2 Inhibitor Business Performance
      • 4.5.4 Merck & Co Antidiabetic SGLT-2 Inhibitor Business Development and Market Status
    • 4.6 Eli Lilly
      • 4.6.1 Eli Lilly Profiles
      • 4.6.2 Eli Lilly Product Information
      • 4.6.3 Eli Lilly Antidiabetic SGLT-2 Inhibitor Business Performance
      • 4.6.4 Eli Lilly Antidiabetic SGLT-2 Inhibitor Business Development and Market Status
    • 4.7 Sanofi
      • 4.7.1 Sanofi Profiles
      • 4.7.2 Sanofi Product Information
      • 4.7.3 Sanofi Antidiabetic SGLT-2 Inhibitor Business Performance
      • 4.7.4 Sanofi Antidiabetic SGLT-2 Inhibitor Business Development and Market Status
    • 4.8 Takeda Pharmaceuticals
      • 4.8.1 Takeda Pharmaceuticals Profiles
      • 4.8.2 Takeda Pharmaceuticals Product Information
      • 4.8.3 Takeda Pharmaceuticals Antidiabetic SGLT-2 Inhibitor Business Performance
      • 4.8.4 Takeda Pharmaceuticals Antidiabetic SGLT-2 Inhibitor Business Development and Market Status
    • 4.9 Novo Nordisk
      • 4.9.1 Novo Nordisk Profiles
      • 4.9.2 Novo Nordisk Product Information
      • 4.9.3 Novo Nordisk Antidiabetic SGLT-2 Inhibitor Business Performance
      • 4.9.4 Novo Nordisk Antidiabetic SGLT-2 Inhibitor Business Development and Market Status
    • 4.10 Servier Laboratories
      • 4.10.1 Servier Laboratories Profiles
      • 4.10.2 Servier Laboratories Product Information
      • 4.10.3 Servier Laboratories Antidiabetic SGLT-2 Inhibitor Business Performance
      • 4.10.4 Servier Laboratories Antidiabetic SGLT-2 Inhibitor Business Development and Market Status
    • 4.11 Boehringer Ingelheim
    • 4.12 Bristol-Myers Squibb

    5 Market Performance for Manufacturers

    • 5.1 Asia-Pacific Antidiabetic SGLT-2 Inhibitor Sales (K Units) and Market Share by Manufacturers 2013-2018
    • 5.2 Asia-Pacific Antidiabetic SGLT-2 Inhibitor Revenue (M USD) and Market Share by Manufacturers 2013-2018
    • 5.3 Asia-Pacific Antidiabetic SGLT-2 Inhibitor Price (USD/Unit) of Manufacturers 2013-2018
    • 5.4 Asia-Pacific Antidiabetic SGLT-2 Inhibitor Gross Margin of Manufacturers 2013-2018
    • 5.5 Market Concentration

    6 Regions Market Performance for Manufacturers

    • 6.1 China Market Performance for Manufacturers
      • 6.1.1 China Antidiabetic SGLT-2 Inhibitor Sales (K Units) and Share of Manufacturers 2013-2018
      • 6.1.2 China Antidiabetic SGLT-2 Inhibitor Revenue (M USD) and Share of Manufacturers 2013-2018
      • 6.1.3 China Antidiabetic SGLT-2 Inhibitor Price (USD/Unit) of Manufacturers 2013-2018
      • 6.1.4 China Antidiabetic SGLT-2 Inhibitor Gross Margin of Manufacturers 2013-2018
      • 6.1.5 Market Concentration
    • 6.2 Japan Market Performance for Manufacturers
      • 6.2.1 Japan Antidiabetic SGLT-2 Inhibitor Sales (K Units) and Share of Manufacturers 2013-2018
      • 6.2.2 Japan Antidiabetic SGLT-2 Inhibitor Revenue (M USD) and Share of Manufacturers 2013-2018
      • 6.2.3 Japan Antidiabetic SGLT-2 Inhibitor Price (USD/Unit) of Manufacturers 2013-2018
      • 6.2.4 Japan Antidiabetic SGLT-2 Inhibitor Gross Margin of Manufacturers 2013-2018
      • 6.2.5 Market Concentration
    • 6.3 South Korea Market Performance for Manufacturers
      • 6.3.1 South Korea Antidiabetic SGLT-2 Inhibitor Sales (K Units) and Share of Manufacturers 2013-2018
      • 6.3.2 South Korea Antidiabetic SGLT-2 Inhibitor Revenue (M USD) and Share of Manufacturers 2013-2018
      • 6.3.3 South Korea Antidiabetic SGLT-2 Inhibitor Price (USD/Unit) of Manufacturers 2013-2018
      • 6.3.4 South Korea Antidiabetic SGLT-2 Inhibitor Gross Margin of Manufacturers 2013-2018
      • 6.3.5 Market Concentration
    • 6.4 Taiwan Market Performance for Manufacturers
      • 6.4.1 Taiwan Antidiabetic SGLT-2 Inhibitor Sales (K Units) and Share of Manufacturers 2013-2018
      • 6.4.2 Taiwan Antidiabetic SGLT-2 Inhibitor Revenue (M USD) and Share of Manufacturers 2013-2018
      • 6.4.3 Taiwan Antidiabetic SGLT-2 Inhibitor Price (USD/Unit) of Manufacturers 2013-2018
      • 6.4.4 Taiwan Antidiabetic SGLT-2 Inhibitor Gross Margin of Manufacturers 2013-2018
      • 6.4.5 Market Concentration
    • 6.5 India Market Performance for Manufacturers
      • 6.5.1 India Antidiabetic SGLT-2 Inhibitor Sales (K Units) and Share of Manufacturers 2013-2018
      • 6.5.2 India Antidiabetic SGLT-2 Inhibitor Revenue (M USD) and Share of Manufacturers 2013-2018
      • 6.5.3 India Antidiabetic SGLT-2 Inhibitor Price (USD/Unit) of Manufacturers 2013-2018
      • 6.5.4 India Antidiabetic SGLT-2 Inhibitor Gross Margin of Manufacturers 2013-2018
      • 6.5.5 Market Concentration
    • 6.6 Southeast Asia Market Performance for Manufacturers
      • 6.6.1 Southeast Asia Antidiabetic SGLT-2 Inhibitor Sales (K Units) and Share of Manufacturers 2013-2018
      • 6.6.2 Southeast Asia Antidiabetic SGLT-2 Inhibitor Revenue (M USD) and Share of Manufacturers 2013-2018
      • 6.6.3 Southeast Asia Antidiabetic SGLT-2 Inhibitor Price (USD/Unit) of Manufacturers 2013-2018
      • 6.6.4 Southeast Asia Antidiabetic SGLT-2 Inhibitor Gross Margin of Manufacturers 2013-2018
      • 6.6.5 Market Concentration
    • 6.7 Australia Market Performance for Manufacturers
      • 6.7.1 Australia Antidiabetic SGLT-2 Inhibitor Sales (K Units) and Share of Manufacturers 2013-2018
      • 6.7.2 Australia Antidiabetic SGLT-2 Inhibitor Revenue (M USD) and Share of Manufacturers 2013-2018
      • 6.7.3 Australia Antidiabetic SGLT-2 Inhibitor Price (USD/Unit) of Manufacturers 2013-2018
      • 6.7.4 Australia Antidiabetic SGLT-2 Inhibitor Gross Margin of Manufacturers 2013-2018
      • 6.7.5 Market Concentration
    • 6.8 Market Performance for Manufacturers
      • 6.8.1 Antidiabetic SGLT-2 Inhibitor Sales (K Units) and Share of Manufacturers 2013-2018
      • 6.8.2 Antidiabetic SGLT-2 Inhibitor Revenue (M USD) and Share of Manufacturers 2013-2018
      • 6.8.3 Antidiabetic SGLT-2 Inhibitor Price (USD/Unit) of Manufacturers 2013-2018
      • 6.8.4 Antidiabetic SGLT-2 Inhibitor Gross Margin of Manufacturers 2013-2018
      • 6.8.5 Market Concentration

    7 Asia-Pacific Antidiabetic SGLT-2 Inhibitor Market Performance (Sales Point)

    • 7.1 Asia-Pacific Antidiabetic SGLT-2 Inhibitor Sales (K Units) and Market Share by Regions 2013-2018
    • 7.2 Asia-Pacific Antidiabetic SGLT-2 Inhibitor Revenue (M USD) and Market Share by Regions 2013-2018
    • 7.3 Asia-Pacific Antidiabetic SGLT-2 Inhibitor Price (USD/Unit) by Regions 2013-2018
    • 7.4 Asia-Pacific Antidiabetic SGLT-2 Inhibitor Gross Margin by Regions 2013-2018

    8 Development Trend for Regions (Sales Point)

    • 8.1 Asia-Pacific Antidiabetic SGLT-2 Inhibitor Sales and Growth, Sales Value and Growth Rate2013-2018
    • 8.2 China Antidiabetic SGLT-2 Inhibitor Sales and Growth, Sales Value and Growth Rate2013-2018
    • 8.3 Japan Antidiabetic SGLT-2 Inhibitor Sales and Growth, Sales Value and Growth Rate2013-2018
    • 8.4 South Korea Antidiabetic SGLT-2 Inhibitor Sales and Growth, Sales Value and Growth Rate2013-2018
    • 8.5 Taiwan Antidiabetic SGLT-2 Inhibitor Sales and Growth, Sales Value and Growth Rate2013-2018
    • 8.6 India Antidiabetic SGLT-2 Inhibitor Sales and Growth, Sales Value and Growth Rate2013-2018
    • 8.7 Southeast Asia Antidiabetic SGLT-2 Inhibitor Sales and Growth, Sales Value and Growth Rate2013-2018
    • 8.8 Australia Antidiabetic SGLT-2 Inhibitor Sales and Growth, Sales Value and Growth Rate2013-2018
    • 8.8 Australia Antidiabetic SGLT-2 Inhibitor Sales and Growth, Sales Value and Growth Rate2013-2018

    9 Upstream Source, Technology and Cost

    • 9.1 Upstream Source
    • 9.2 Technology
    • 9.3 Cost

    10 Channel Analysis

    • 10.1 Market Channel
    • 10.2 Distributors

    11 Consumer Analysis

    • 11.1 Hospitals Industry
    • 11.2 Clinics Industry
    • 11.3 Other Industry

    12 Market Forecast 2019-2024

    • 12.1 Sales (K Units), Revenue (M USD), Market Share and Growth Rate 2019-2024
      • 12.1.1 Asia-Pacific Antidiabetic SGLT-2 Inhibitor Sales (K Units), Revenue (M USD) and Market Share by Regions 2019-2024
      • 12.1.2 Asia-Pacific Antidiabetic SGLT-2 Inhibitor Sales (K Units) and Growth Rate 2019-2024
      • 12.1.3 China Antidiabetic SGLT-2 Inhibitor Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
      • 12.1.4 Japan Antidiabetic SGLT-2 Inhibitor Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
      • 12.1.5 South Korea Antidiabetic SGLT-2 Inhibitor Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
      • 12.1.6 Taiwan Antidiabetic SGLT-2 Inhibitor Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
      • 12.1.7 India Antidiabetic SGLT-2 Inhibitor Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
      • 12.1.8 Southeast Asia Antidiabetic SGLT-2 Inhibitor Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
      • 12.1.9 Australia Antidiabetic SGLT-2 Inhibitor Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
      • 12.1.10 Antidiabetic SGLT-2 Inhibitor Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
    • 12.3 Sales (K Units), Revenue (M USD) by Types 2019-2024
      • 12.3.1 Overall Market Performance
      • 12.3.2 Canagliflozin Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
      • 12.3.3 Empagliflozin Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
      • 12.3.4 Dapagliflozin Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
      • 12.3.5 Other Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
    • 12.4 Sales by Application 2019-2024
      • 12.4.1 Overall Market Performance
      • 12.4.2 Hospitals Sales and and Growth Rate 2019-2024
      • 12.4.3 Clinics Sales and and Growth Rate 2019-2024
      • 12.4.4 Other Sales and and Growth Rate 2019-2024
    • 12.5 Price (USD/Unit) and Gross Profit
      • 12.5.1 Asia-Pacific Antidiabetic SGLT-2 Inhibitor Price (USD/Unit) Trend 2019-2024
      • 12.5.2 Asia-Pacific Antidiabetic SGLT-2 Inhibitor Gross Profit Trend 2019-2024

    13 Conclusion

    Geographically, this report split Asia-Pacific into several key Regions, with sales (K Units), revenue (Million USD), market share and growth rate of Antidiabetic SGLT-2 Inhibitor for these regions, from 2012 to 2023 (forecast), including
    China
    Japan
    South Korea
    Taiwan
    India
    Southeast Asia
    Australia

    Asia-Pacific Antidiabetic SGLT-2 Inhibitor market competition by top manufacturers/players, with Antidiabetic SGLT-2 Inhibitor sales volume, price, revenue (Million USD) and market share for each manufacturer/player; the top players including
    Pfizer
    AstraZeneca
    Johnson & Johnson
    GlaxoSmithKline
    Merck & Co
    Eli Lilly
    Sanofi
    Takeda Pharmaceuticals
    Novo Nordisk
    Servier Laboratories
    Boehringer Ingelheim
    Bristol-Myers Squibb

    On the basis of product, this report displays the sales volume (K Units), revenue (Million USD), product price (USD/Unit), market share and growth rate of each type, primarily split into
    Canagliflozin
    Empagliflozin
    Dapagliflozin
    Other

    On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume (K Units), market share and growth rate of Antidiabetic SGLT-2 Inhibitor for each application, including
    Hospitals
    Clinics
    Other

    If you have any special requirements, please let us know and we will offer you the report as you want.

    Buy now